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OBJECTIVES: One of the concerns regarding care for adults
with spina biﬁda is the high cost of treating secondary condi-
tions, many of which are considered preventable. To determine
if specialty care for spina biﬁda may act to contain costs by
reducing, through prevention, the frequency and severity of
costly secondary conditions. METHODS: We obtained retro-
spective claims data from the Washington State Department of
Social and Health Services Health and Recovery Services Admin-
istration (HRSA). Fee-for-service claims data on all services, and
eligibility records were obtained for Medicaid recipients of any
age diagnosed with spina biﬁda (ICD9 code of 741.xx), between
July 1, 2000 and December 31, 2004. Using multiple regression,
we examined the relationship between log health-related charges
(hospital, pharmaceuticals, dental care, and other medical) and
demographic variables (race, sex, age, and urban vs. rural resi-
dence), number of months enrolled in the Medicaid program, the
Charlson comorbidity index, and contact with clinics specializ-
ing in the care of spina biﬁda patients (N = 364). RESULTS:
Comorbidity was the strongest predictor of health charges. Our
results also suggest that, controlling for other factors, contact
with clinics specializing in spina biﬁda care had no signiﬁcant
impact on combined charges (F(2356) = 2.26, p = n.s). However,
there is a positive simple correlation between log total charges
and being seen in an adult spina biﬁda specialty clinic. The rela-
tionship persists when comorbidities and demographic variables
are considered. CONCLUSION: Specialty care for Spina Biﬁda
may not offer a signiﬁcant advantage to patients or payors. The
correlation between log total charges and adult specialty care
may indicate that specialty care is more expensive. Although our
analysis controlled for patient severity, this ﬁnding could also
reﬂect a migration of more costly and troublesome cases to spe-
cialty clinics.
PND6
COST-EFFECTIVENESS OF SCREENING FOR COGNITIVE
IMPAIRMENT IN OLDER POPULATIONS: IMPLICATIONS FOR
ALZHEIMER’S DISEASE CARE
Neumann PJ1, Cohen JT1, Zhang B2, Fillit HM3
1Tufts-New England Medical Center, Boston, MA, USA, 2Boston
Health Economics, Waltham, MA, USA, 3Institute for the Study of
Aging, New York, NY, USA
OBJECTIVES: We investigated the cost-effectiveness of screen-
ing for cognitive impairment in older populations, focusing on
consequences for Alzheimer’s disease (AD) management. We also
examined how cost-effectiveness varies with assumptions about
the age of individuals screened, and with the effectiveness and
costs of screening, diagnosis and treatment. METHODS: We
developed a decision-analytic model to examine the incremental
cost-effectiveness of one-time screening compared to no screen-
ing in different age groups. We assumed that all screened indi-
viduals would receive a rapid mental exam, followed by a
complete medical work-up including diagnostic imaging if AD
was suspected. We assumed that patients identiﬁed as having AD
receive a cholinesterase inhibitor if they had mild or moderate
AD, and that patients with moderate AD also receive meman-
tine. Health effects are presented in terms of quality-adjusted life
years (QALYs) gained. Future costs and QALYs are discounted
at 3 percent annually. Costs are expressed in US $2004. Para-
meter estimates are based on publicly available data. Key
assumptions and estimates are tested in sensitivity analyses.
RESULTS: The model estimates that the cost-effectiveness of
screening all 80 year olds is approximately $63,000/QALY. Cost-
effectiveness is sensitive to the age of the population screened,
ranging from $490,000/QALY if done in 65 year olds to
$48,000/QALY for 85 year olds. Results are also sensitive to
assumptions about the costs and effects of AD medications and
costs and accuracy of screening and diagnosis. CONCLUSION:
Given currently available technology, population-wide screening
for cognitive impairment for all Americans aged 80 and older
could represent reasonable value for money, though there is
uncertainty about the accuracy and cost of screening and follow
up treatment. Policy makers should revisit the issue as diagnos-
tic and management techniques advance, because improvements
will make widespread screening in younger old populations more
attractive from an economic standpoint.
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PHARMACOECONOMIC ANALYSIS OF ANTIEPILEPTIC DRUGS
IN THE TREATMENT OF THE IDIOPATHIC GENERALIZED
EPILEPSIES
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OBJECTIVES: To make a pharmacoeconomic assessment of the
antiepileptic drugs valproate, lamotrigine and topiramate in idio-
pathic generalized epilepsy treatment in Russia. METHODS:
The pharmacoeconomic assessment was based on the results of
a retrospective clinical study “The relationship between treat-
ment with valproate, lamotrigine and topiramate and the prog-
nosis of the idiopathic generalized epilepsies” (A. Nicolson, R.E.
Appleton, D.W. Chadwick and D.F. Smith—J. Neurol. Neuro-
surg. Psychiatry 2004;75;75–79). 731 of those patients covered
by the study underwent monotherapy with one of the anticon-
vulsants valproate, lamotrigine and topiramate. 52.1 percent of
those patients treated with valproate achieved remission. The
same ﬁgures for topiramate and lamotrigine at 34.6 and 16.7
percent, respectively. RESULTS: The study assessed the direct
medical costs of antiepileptic therapy. The analysis was based 
on the price of the original drugs, Depakine, Lamictale and
Topamax. The average daily dose was 1286 mg for valproate,
324 mg for lamotrigine and 256 mg for topiramate. Annual
therapy costs per patient were calculated for each drug. Thus,
for Depakine, Lamictale and Topamax these were 18,776,
53,217 and 94,374 rubles (1 USD = 26.5 RUR), respectively. The
following results were obtained while calculating the cost-effec-
tiveness (CE) coefﬁcient: 36,037.62 for Depakine, 318,664.67
for Lamictale and 272,758.38 for Topamax. Valproate
(Depakine) as compared with lamotrigine (Lamictale) and topi-
ramate (Topamax) was shown to have the lowest CE coefﬁcient.
CONCLUSION: Valproate may be the most effective antiepilep-
tic drug in anti-IGE monotherapy in pharmacoeconomic terms.
The use of valproate as the ﬁrst-choice drug helps achieve a pos-
sible economic gain of 1,003,889 rubles annually for a group of
100 patients increasing cost-effectiveness almost two times.
